scispace - formally typeset
Journal ArticleDOI

Neoadjuvant Concurrent Chemoradiation for Advanced Esthesioneuroblastoma: A Case Series and Review of the Literature

Reads0
Chats0
TLDR
Two cases of advanced ENB are presented at this institution treated with a preoperative concurrent radiochemotherapy in a manner akin to that of small-cell carcinoma of the lung.
Abstract
Esthesioneuroblastoma (ENB) is a rare malignancy arising from the olfactory epithelium of the nasal vault. ENB accounts for 3% to 6% of all intranasal tumors and has the best prognosis among sinonasal malignancies with neuroendocrine differentiation. The optimal treatment continues to be controversial, but the benefit of adjuvant therapy, particularly radiotherapy, has been well described in the literature. The largest reported series evaluated neoadjuvant radiotherapy of 50 Gy, with or without neoadjuvant chemotherapy, and found improved resectability with improved patient survival. We present two cases of advanced ENB at our institution treated with a preoperative concurrent radiochemotherapy in a manner akin to that of small-cell carcinoma of the lung.

read more

Citations
More filters
Journal ArticleDOI

Optimization of long-term outcomes for patients with esthesioneuroblastoma.

TL;DR: The purpose of this study was to review the long‐term outcomes of patients diagnosed with esthesioneuroblastoma treated at a single institution to determine factors associated with improved disease control and survival.
Journal ArticleDOI

Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome

TL;DR: Low and high-grade ENB display distinct patterns at presentation and relapse, leading to different prognosis, therefore, they may be regarded as distinct entities.
Journal ArticleDOI

Esthesioneuroblastoma: A Comprehensive Review of Diagnosis, Management, and Current Treatment Options.

TL;DR: Surgical resection followed by radiotherapy is the current standard for treatment for higher-grade lesions and endoscopic endonasal approach is gaining further recognition with more favorable outcomes and better survival rates than open surgery.
Journal ArticleDOI

Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy.

TL;DR: Proton therapy was associated with significantly reduced radiation dose to assessed non-target normal tissues and a reduced rate of gastrostomy tube dependence and opioid pain medication requirements and warrants further evaluation in larger studies.
Journal ArticleDOI

Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma.

TL;DR: The high risk of locoregional failure in ENB justifies the use of multimodal therapy and elective LNI might prevent regional failure in locally advanced disease.
References
More filters
Journal ArticleDOI

Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer

TL;DR: Combined treatment for advanced head and neck cancer is more efficacious and not more toxic than hyperfractionated irradiation alone.
Journal ArticleDOI

Olfactory neuroblastoma—A clinical analysis of 17 cases

TL;DR: Of 17 patients in this series, 13 or 76% were alive without disease following treatment by surgery, irradiation, and combination of these two methods, and a treatment policy for this disease is presented.
Journal ArticleDOI

Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

TL;DR: Concomitant CT offered improved disease control and survival in advanced head and neck cancer patients due to increased acute toxicity, more supportive care is demanded when CT is given simultaneously.
Journal ArticleDOI

Overview of Combined Modality Therapies for Head and Neck Cancer

TL;DR: It is concluded that curability of nasopharyngeal carcinoma with a combined modality approach appears to be an achievable goal, but adequate evaluation in large-scale randomized trials is hampered by low accrual to clinical trials.
Related Papers (5)